Gallus Biopharmaceuticals Enters Clinical Supply Agreement with Genzyme for Niemann Pick Type B Disease

Gallus Biopharmaceuticals has signed a development and manufacturing supply agreement with Genzyme, a Sanofi company. As part of the multiyear agreement Gallus will provide process and method development, scale-up, clinical supply, and preparation for commercial manufacturing for an infused protein-based therapy targeting the rare disease, Niemann-Pick type B.

The firm, based in St. Louis, Missouri, was established in 2010 and acquired a commercial biopharmaceutical manufacturing facility from Johnson & Johnson, Centocor division in 2011. In addition to process development and clinical supply services, Gallus currently produces two commercial products that are distributed globally.

Source: Gallus Biopharmaceuticals